Teragen Etex is showing strong performance. This is interpreted as Teragen Etex, which possesses infertility solutions, gaining attention due to news that the Yoon Suk-yeol administration plans to significantly expand support for infertile couples to overcome low birth rates.
As of 9:28 AM on the 21st, Teragen Etex is trading at 4,815 KRW, up 4.9% compared to the previous day.
According to the presidential office and various ministries on the previous day, the government plans to announce a comprehensive low birth rate countermeasure soon and actively promote it. Last year, South Korea's total fertility rate was 0.78, which is expected to be the lowest among OECD member countries.
Accordingly, the government, judging that previous low birth rate policies have not been effective, is known to focus this new measure on increasing the possibility of a fundamental solution.
In particular, expanding support for infertile couples has been discussed as the most direct low birth rate countermeasure. As of last year, about 250,000 people nationwide have been officially diagnosed with infertility. However, health insurance support is limited to about 5 to 9 procedures per treatment, and the out-of-pocket ratio is around 30%. Additional support for non-reimbursed items also has income restrictions, such as being limited to those with income below 180% of the median income. Recently, Seoul City announced it would provide support regardless of income level, but nationwide support systems remain insufficient.
Therefore, the Yoon Suk-yeol administration plans to establish support measures where, in principle, there will be no income criteria or limits on the number of treatments, and the state will fully take responsibility for infertile couples who wish to have children.
Meanwhile, Teragen Etex’s subsidiary, Teragen Genome Care, provides solutions that increase implantation and pregnancy success rates by selecting genetically normal embryos without abnormalities through Korea’s first NGS-based PGT test (preimplantation genetic testing) and then implanting them. They also offer various infertility treatments utilizing genetic analysis technologies, such as chromosomal abnormality testing for in vitro fertilized embryos and uterine receptivity testing for mothers.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
